ADAMAS PHARMACEUTICALS, INC. (NASDAQ:ADMS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
its Annual Meeting of Stockholders (the Annual Meeting) at 1800
Powell Street, Emeryville, California 94608. Stockholders who
owned the Companys common stock at the close of business on April
4, 2017, the record date for the Annual Meeting, were entitled to
vote at the Annual Meeting. As of the record date, 22,321,984
shares of the Companys common stock were outstanding and entitled
to vote at the Annual Meeting. At the Annual Meeting, 20,248,115
shares of the Companys common stock were voted in person or by
proxy for the two proposals set forth below, each of which is
described in the Companys Definitive Proxy Statement on Schedule
14A filed with the U.S. Securities and Exchange Commission on
April 18, 2017.
below to the Companys Board of Directors to hold office until the
2020 Annual Meeting of Stockholders or until their successors are
elected.
|
Class I Director Nominees
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|||
|
Michael F. Bigham
|
14,949,937
|
690,954
|
4,607,224
|
|||
|
David L. Mahoney
|
14,907,838
|
733,053
|
4,607,224
|
|||
|
John MacPhee
|
14,602,264
|
1,038,627
|
4,607,224
|
Registered Accounting Firm
PricewaterhouseCoopers LLC as the independent registered public
accounting firm of the Company for its fiscal year ending
December 31, 2017.
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|||
|
20,236,092
|
12,023
|
About ADAMAS PHARMACEUTICALS, INC. (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures). ADAMAS PHARMACEUTICALS, INC. (NASDAQ:ADMS) Recent Trading Information
ADAMAS PHARMACEUTICALS, INC. (NASDAQ:ADMS) closed its last trading session up +0.89 at 16.27 with 81,307 shares trading hands.